 Lymphoma, B-Cell
"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 1 | 4 | | 1995 | 1 | 0 | 1 | | 1996 | 3 | 1 | 4 | | 1997 | 0 | 1 | 1 | | 1998 | 2 | 3 | 5 | | 1999 | 0 | 1 | 1 | | 2000 | 3 | 1 | 4 | | 2001 | 5 | 2 | 7 | | 2002 | 3 | 0 | 3 | | 2003 | 4 | 1 | 5 | | 2004 | 1 | 1 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 6 | 0 | 6 | | 2014 | 1 | 1 | 2 | | 2015 | 5 | 0 | 5 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 0 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 4 | 0 | 4 | | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Tanager KS, Yu J, Chiu BC, Carll TC, Tatarian AH, Riedell P, Smith S, Kline J, Venkataraman G. Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969.
-
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
-
Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, Litzow MR, Stone RM, Sharon E, Erba HP. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 May 10; 40(14):1574-1582.
-
Zamò A, Johnston P, Attygalle AD, Laurent C, Arber DA, Fend F. Aggressive B-cell lymphomas with a primary bone marrow presentation. Histopathology. 2020 Sep; 77(3):369-379.
-
Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
-
Qiu Z, Lin AP, Jiang S, Elkashef SM, Myers J, Srikantan S, Sasi B, Cao JZ, Godley LA, Rakheja D, Lyu Y, Zheng S, Madesh M, Shiio Y, Dahia PLM, Aguiar RCT. MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chem Biol. 2020 05 21; 27(5):538-550.e7.
-
Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
-
Parker K, Venkataraman G. Challenges in the Diagnosis of Gray Zone Lymphomas. Surg Pathol Clin. 2019 Sep; 12(3):709-718.
-
Coffey GP, Feng J, Betz A, Pandey A, Birrell M, Leeds JM, Der K, Kadri S, Lu P, Segal J, Wang YL, Michelson G, Curnutte JT, Conley PB. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clin Cancer Res. 2019 02 15; 25(4):1174-1184.
-
Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|